Abstract: A sterile aqueous formulation of a carbonic anhydrase inhibitor such as brinzolamide in combination with polymers like Soluplus® and a surfactant like polysorbate 80, as well as methods of preparation thereof, is disclosed. The formulation relates to the highly solubilized or an amorphous form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.

Abstract: Described is a targeted molecular scaffold for construction of a metabolic inhibitor loaded with cancer-cell specific activity and anti-tumor immunity. Incorporation of a mitochondria targeting moiety such as triphenylphosphonium cation through a biodegradable linker in allowed for mitochondria targeting of certain metabolic inhibitors like dichloroacetic acid (DCA).

Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.

Abstract: The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present invention provides heavy chain immunoglobulins of the VHH type or fragment thereof having affinity for a target antigen of interest, including glycoprotein D2 (gD2) of HSV-2 or antigen thereof, and for envelope proteins of HIV-1 or an antigen thereof linked to Pseudomonas exotoxin A or functional fragments thereof. Also included are multimeric forms of the immunoglobulins and their use in the prevention and/or treatment of HSV2 and/or HIV-1.

Abstract: Disclosed herein are microvessel endothelial cell surface markers and methods, compositions, agents, and kits relating to those surface markers.

Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: The technology described herein is directed to agonists of e.g. Esr2, Dlx5, and/or Egr3, for the inhibition of cancer cells (e.g. squamous carcinoma cancer cells) and the treatment of cancer.

Abstract: This disclosure relates to a tattoo decal containing bacteria that can be applied to skin and function as both a monitoring sensor and a visual indicator. In particular, a temporary tattoo containing a bacteria composite that may be selected or “programmed” to sense, detect, or otherwise react to a variety of stimuli for use in a variety of applications and industries is disclosed.

Abstract: The application relates to methods for determining a parameter such as toxicity and pharmacokinetic behavior for a pharmaceutical compound against a disease or disorder. The test animals being used are non-human animals not suffering from or is not showing symptoms or signs of the disorder and which do not provoke an immune response against said pharmaceutical compound. These animals are obtainable by administration of a peptide comprising an oxidoreductase motif further comprising an NKT peptide epitope or an MCH class II T cell epitope of said pharmaceutical compound, wherein said motif and said epitope are separated by a linker of between 0 and 4 amino acids.

Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

Abstract: A polybutylacrylate-based nanocomposite photoacoustic imaging agent includes a biomedical material such as polybutylacrylate used as a main component and methylene blue or indocyanine green used as an entrapped component with particle diameters of 525.1 nm and 272.0 nm and electric potentials of ?4.52 mV and ?5.98 mV respectively. The preparation method of the polybutylacrylate-based nanocomposite photoacoustic imaging agent with the features of moderate eco-friendliness, low power consumption, and free of three industrial wastes, radiation, and noise pollution may be used for industrial production.

Abstract: Disclosed arc PARP-1 inhibitors, which can be 18P-labeled for use as tracers in positron emission tomographic (PET) imaging. Further disclosed are methods of synthesis. Of the compounds synthesized, 2-[p-(2-Fluoroethoxy)phenyl]-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7-tetraen-9-one (12) had the highest inhibition potency for PARP-1 (IC50=6.3 nM). Synthesis of [18F]-12 is disclosed under conventional conditions in high specific activity with 40-50% decay-corrected yield, MicroPET imaging using [18F]-12 in MDA-MB-436 tumor-bearing mice demonstrated accumulation of [18F]-12 in a tumor. Binding, can be blocked by olaparib. The compounds have utility for tumor imaging.

Abstract: This present invention relates to the carbon nanotubes as composites with materials such as elastomers, thermosets and thermoplastics or aqueous dispersions of open-ended carbon nanotubes with additives. A further feature of this invention relates to the development of a concentrate of carbon nanotubes with an elastomer wherein the concentrate can be further diluted with an elastomer and other polymers and fillers using conventional melt mixing equipment.

Abstract: An ultraviolet disinfection system to generate UVC radiation inside athletic clothing, gear and other items to be decontaminated. The system includes a plurality of UVC lamps vertically disposed in a housing and having UVC transmissive lamp enclosures over which items to be decontaminated are placed. The system has a microprocessor based controller and can kill pathogens including Clostridium difficile in 30 seconds or less.

Abstract: A device is presented for disinfecting needleless connectors. The device has a housing that contains a UV light source. The UV light source is operably connected to a power source. The housing has a receptacle configured to selectively receive a shield. The shield has an inner reflective chamber with an internal surface that reflects UV light. In use, the UV light source can illuminate a needleless connector inserted within the shield.

Abstract: A liquid treatment method according to an aspect of the present disclosure comprises: starting application of a power between a pair of electrodes to generate plasma, which causes active species to be produced in a liquid; measuring the hydrogen ion concentration in the liquid while the plasma is generated; measuring a time elapsed after the starting the application of the power; and stopping the application of the power when a value calculated by (a) multiplying the hydrogen ion concentration by the elapsed time or (b) integrating the hydrogen ion concentration with respect to the elapsed time is larger than a first threshold.

Abstract: An apparatus and method of producing an atmospheric non-equilibrium plasma (ANEP) in a sealed container having a selected working gas and an object to be treated is described. A variety of working gas mixtures including air, O2, N2, CO2, He and Ar, in combination with a range of ionization gradients, voltages and ANEP column lengths was investigated so as to establish effective ranges of the variables using the sterilization of a sample as a measure of effectiveness. Certain combinations of working gas, voltage gradient, voltage or ANEP column length were found to have greater effectiveness. The approach may be used for food products, medical equipment, or other objects where treatment with reactive gas atmospheres is effective.

Abstract: A decontamination operation chamber is partitioned into a first operation chamber and a second operation chamber. A connecting portion that connects the first operation chamber and the second operation chamber can be closed. The pressure of the first operation chamber and the second operation chamber is adjusted by a pressure-adjusting mechanism. When the connecting portion is opened and the first operation chamber and the second operation chamber are connected, an inlet portion for the first operation chamber and an outlet portion for the second operation chamber are closed and air flow is generated from the second operation chamber to the first operation chamber by the pressure-adjusting mechanism. When carrying an object into an aseptic manipulation chamber, the object is housed in the first operation chamber and a first decontamination operation is performed, then the object is transferred to the second operation chamber and a second decontamination operation is performed.

Abstract: An odor removal assembly comprising a container that, when open, allows a user to place items into the bag's interior, and when closed, prevents a user from placing items into the interior of the bag. The container may include a fastening mechanism for closing the container. The assembly includes an ozone generator that generates ozone and expels the ozone through a conduit that extends between an outlet of the ozone generator and the interior of the container. The assembly may also include second container configured for placement within the first container. In such embodiments, a user may utilize a portable bag for use with the odor removal assembly without having to carry around the actual ozone generator. Rather, the user may insert the second container into the first in order to utilize the odor removal assembly.

Abstract: Systems and methods for sanitization of surfaces, such as hands, are provided. In general, the described techniques utilize a system including a housing having an active agent receptacle in fluid communication with at least one nozzle, and an air pump in fluid communication with the at least one nozzle. The system also includes a control module configured to control the delivery of an active agent as an aerosol spray through the at least one nozzle in a delivery dose. The delivery dose is expelled onto the surface as a thin uniform layer and dried such that the entire surface sanitization process is completed in less than or equal to 5 seconds. The active agent receptacle can be configured to receive a removable and replaceable cartridge carrying the active agent.

Abstract: An ultraviolet radiation sanitation system which is portable and which operates on battery power to generate UVC radiation to decontaminate bathrooms on aircraft and other small rooms or enclosed areas. The system includes one or more low pressure high output mercury or amalgam UVC lamps mounted on a housing which contains a battery powered power supply, lamp ballasts and control circuitry. The housing also includes a control panel having controls and indicators for system operation. A motion detector is provided on the housing to shut off the system in the presence of detected motion which would occur by the presence of a person. The housing is mounted on a tripod or other stand to support the system on an aircraft bathroom floor or other location in which the system is to be deployed.

Abstract: In-wall dispensing modules, such as room freshener modules, can reside in a housing with a cover that can be opened to access an interior space of the module to, inter alia, replace used containers. The housings are configured to reside inside a wall of a room. The front cover can be a planar cover that is flush, slightly recessed or slightly protrudes from the wall. The housings can be a “custom” housing size and/or may be configured to occupy a single gang box or a compartment of a multi-gang junction box. The modules can include an actuator that can cause a canister to emit scented fluid at desired intervals and/or on-demand. The modules can have a User Interface (UI) wireless and/or wired connection to a whole-house “smart” system.

Abstract: Systems and methods for managing scent in an environment include receiving data from sensors disposed in an environment regarding an indication that a service is being delivered in the environment and identifying remote atomizing scent diffusion devices disposed in the environment, wherein each scent diffusion device comprises a communications facility that enables transmitting signals to and receiving signals from the remote computer. Based on the indication, an electronic data structure is created defining a physical operational state of the scent diffusion devices, including data specifying at least one of a production of a scent that is intended to be a complement to the service, a fan speed of a fan in the diffusion device that moves particles carrying a scent, and a voltage of a pump of the diffusion device. The diffusion devices are caused to implement the at least one defined operational state.

Abstract: Systems and methods for managing scent in an environment include disposing scent diffusion devices within the environment, wherein the diffusion devices comprise a communications facility that enables transmitting signals to and receiving signals from a non-fragrance dispensing, wide-area network gateway device that receives communication and control functions from a remote computer for distribution to the plurality of scent diffusion devices. A sensor in the environment transmits sensor data to the remote computer. A scent parameter for scenting the environment is received at the remote computer. Diffusion of a liquid from the scent diffusion devices is controlled by the network gateway device the to achieve the scent parameter, wherein controlling includes setting or adjusting an operation parameter of one or more of the scent diffusion devices in response to the sensor data.

Abstract: This document describes a high intensity air purifier, a super oxidation purifier, and a controller for controlling operation of any of various purification systems. The air purifier includes an air purifier system coupled within a housing having an air inlet and an air outlet. The air purifier system includes a pre-filter coupled to the air inlet, an axial fan for receiving and forwarding air from the air inlet. The air purifier further includes a UV reaction chamber having a UV-light source for providing UV light to the forwarded air from the air inlet and a reflective lining to reflect the provided UV light, to provide UV purified air from the UV reaction chamber. The air purifier further includes a chemical catalyst cartridge for receiving the UV purified air from the UV reaction chamber, for further purifying the UV purified air, and a post filter coupled to the air outlet.

Abstract: An ultraviolet irradiation apparatus includes: a first substrate; a second substrate; electrodes disposed directly or indirectly on the first substrate; a dielectric layer covering the electrodes; a sealant joining together the first and second substrates; a light-emitting layer that is disposed directly or indirectly on the dielectric layer and/or a surface of the second substrate; and a reaction vessel disposed directly or indirectly on a surface of the second substrate. The reaction vessel includes a tubular structure, an inlet channel and an outlet channel. The tubular structure has a ratio ha/hc of 5 to 10, where ha is a diameter of a circle inscribed in an inner bottom surface of the tubular structure, and hc is an inner height of the tubular structure.

Abstract: An oxygen catalyst-containing structure comprising a first layer encapsulated by a second layer is provided, where the first layer includes an oxygen catalyst and the second layer is free of an oxygen catalyst. A method of making an oxygen catalyst-containing structure comprising a first layer and a second layer is also provided where the first layer includes an oxygen catalyst, the second layer is free of an oxygen catalyst, and the first layer is encapsulated by the second layer. The method includes impregnating a first solution containing a first superabsorbent polymer with an oxygen catalyst; allowing the first solution to gel to form the first layer; coating the first layer with a second solution containing a second superabsorbent polymer; and allowing the second solution to gel to form the second layer.

Abstract: The invention provides a ready to use biodegradable and biocompatible device and a method for manufacturing thereof. The device of present invention is a novel porous scaffold which can be used as carrier of plurality of therapeutics to quickly stop bleeding and other biomaterial and biomedical application. The scaffold can be directly applied to the spot of the wound and will stop bleeding within no time. The scaffold of the present invention comprises of combined application of air dry and freeze dry method. The scaffold also comprises of excellent ventilations properties and easy removal of the scaffold without causing any extra hemorrhage to the wound.

Abstract: An oxygen coating composition comprising a hydrogel matrix and oxygen containing cells that are non-uniformly distributed in the matrix, wherein the oxygen containing cells include a superabsorbent polymer and an oxygen catalyst is provided. A method of making an oxygen coating composition is also provided. The method includes polymerizing a superabsorbent polymer and an oxygen catalyst to form a sheet; dehydrating the sheet; pulverizing the sheet to form a superabsorbent polymer/oxygen catalyst powder; and combining the powder with a film forming polymer to form a hydrogel matrix in which the powder is dispersed is also provided. The particular components and arrangement of the oxygen coating composition can improve the shelf life and stability of the coating composition, and the method by which the composition is made can be part of a continuous process rather than a batch type process.

Abstract: A method and device for use in stress female urinary incontinence. A small, flexible adhesive patch is applied directly to the clitoris of a person suffering from stress female urinary incontinence. The adhesive is of a type sufficient to stimulate the mechanoreceptors located in the clitoris whereby to inhibit discharge from the bladder. The patch is formed of a backing sheet of an impervious material containing adhesive on one side. A release liner prevents the adhesive from drying out.

Abstract: A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: Methods for improving the antibacterial, osteoconductive, and/or osteoinductive characteristics of silicon nitride and/or other ceramic materials, particularly to make them more suitable for use in manufacturing biomedical implants. In some embodiments and implementations, the surface chemistry and/or morphology of a silicon nitride bioceramic may be modulated significantly through thermal, chemical, and/or mechanical treatments to achieve such advantageous results. A portion of the resulting material, such as a glaze or upper layer of the material, may be separately produced as a powder or frit, for example, and used in manufacturing biomedical implants and/or other products, such as by using such portion of the material as a coating or filler. In other embodiments the surface material may be separately manufactured as a silicon oxynitride monolith.

Abstract: A polymeric scaffold contains pendant liquid crystal side chains and has fully interconnected pores. Such a polymeric scaffold will preferably be 3D in nature and elastomeric, biocompatible and biodegradable. Such 3D liquid crystal elastomer (LCE) scaffolds can be used for various biomedical applications, including cell culture applications. A method for the production of such a polymeric scaffold containing liquid crystals and having interconnected pores is also disclosed that uses a metal foam sacrificial template as a scaffold to produce the polymeric smart response scaffold of the present invention. Consistent and controlled pore sizes result from etching the sacrificial metal foam template away from the polymeric scaffold, permitting the incorporation of growth factors, when needed, for enhancing cell viability and proliferation.

Abstract: A system consisting of a component coating a particulate scaffold is able to transfer the coating to an exposed surface in order to yield beneficial effects. The system is useful for many applications, including the treatment of individuals suffering from a disease, cancer, an ailment, an infection, a toxin, or other syndrome, as well as for numerous non-treatment purposes requiring the coating of exposed surfaces.

Abstract: A system consisting of a component coating a particulate scaffold is able to transfer the coating to an exposed surface in order to yield beneficial effects. The system is useful for many applications, including the treatment of individuals suffering from a disease, cancer, an ailment, an infection, a toxin, or other syndrome, as well as for numerous non-treatment purposes requiring the coating of exposed surfaces.

Abstract: The subject invention pertains to compositions and methods for promoting repair of damaged nerve tissue using nerve grafts and preparation of nerve grafts. The compositions and methods of the subject invention can be employed to restore the continuity of nerve interrupted by disease, traumatic events or surgical procedures. Compositions of the subject invention comprise one or more chondroitin sulfate proteoglycan (CSPG)-degrading enzymes that promote axonal penetration into damaged nerve tissue and nerve graft. The invention also concerns methods for promoting repair of damaged nerve tissue using the present compositions and nerve tissue treated according to such methods. The invention also includes storage solutions for nerve tissue.

Abstract: Provided are a method of producing a cross-linked PVA-ECM composite, and a PVA-ECM composite produced by using the method.

Abstract: Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury.

Abstract: A hydrogel and a method for manufacturing the same. The hydrogel, which can be freely used during treatment irrespective of the shape of a bone defect region, has a decomposition rate capable of being regulated in situ and can thus be rapidly decomposed over a certain time, i.e., after the completion of bone regeneration. Furthermore, a hydrogel membrane using the hydrogel which is applied to a bone defect region irrespective of the shape thereof, and a method for manufacturing the same.

Abstract: A method of creating a drug eluting system for hernia repair in a patient is provided. The includes providing an implantable mesh for hernia repair comprised of at least one of polytetrafluoroethylene fibers or polytetrafluoroethylene filaments, wherein the at least one of the polytetrafluoroethylene fibers or polytetrafluoroethylene filaments is at least one of directionally or non-directionally oriented, positioning a pharmaceutical agent on the implantable mesh, and coating at least a portion of the at least one of the polytetrafluoroethylene fibers or polytetrafluoroethylene filaments and the pharmaceutical agent with a polymer, wherein the implantable mesh is configured to be positioned in the body of the patient during the repair of the hernia and the pharmaceutical agent elutes from the implantable mesh into the body of the patient at the site of the hernia repair.

Abstract: A new material was assessed in a patellar reattachment model in sheep and evaluated using histology and biomechanical testing. Overall, these materials showed they produced minimal reactivity histologically. The new material had higher failure strength overall compared to a previous study with the control material as repairs completed with PLG/CS/TCP anchors were significantly stronger compared to repairs with PLLA anchors.

Abstract: Described here is a graphene-catalysts conjugate, comprising: a graphene support; a first catalyst conjugated to the graphene support; and a second catalyst conjugated to the graphene support, and the second catalyst is different from the first catalyst. In some embodiments, the first catalyst and the second catalyst correspond to a tandem catalytic system to drive a chemical transformation.